| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
|
|
|
||||||||
|
||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Basic Science Investigation |
1 Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland; 2 Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center Nashville, Nashville, Tennessee; and 3 Department of Nuclear Medicine, Yonsei University Medical College, Seoul, South Korea
Correspondence: For correspondence or reprints contact: Amira K. Brown, PhD, Molecular Imaging Branch, National Institute of Mental Health, 31 Center Dr., Room B2/B34, Bethesda, MD 20892-2035. E-mail: amirabrown{at}mail.nih.gov
11C-PBR28 ([methyl-11C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine) is a recently developed radioligand to image peripheral benzodiazepine receptors (PBRs) in brain. The aim of this study was to estimate the human radiation doses of 11C-PBR28 based on biodistribution data in monkeys and humans. In addition, we scanned 1 human subject who fortuitously behaved as if he lacked the PBR binding protein. Methods: Whole-body PBR images were acquired after intravenous bolus administration of 11C-PBR28 in 7 healthy humans (651 ± 111 MBq) and 2 rhesus monkeys (370 ± 59.9 MBq). One monkey was scanned after receptor blockade with PK 11195 (10.7 mg/kg intravenously). Results: For typical subjects (subjects 1–6), the 3 organs with highest exposure were those with the high PBR densities (kidneys, spleen, and lungs), and the effective dose was 6.6 µSv/MBq. The unusual subject (subject 7) had 60%–90% less uptake in these 3 organs, resulting in 28% lower effective dose. The activity in the baseline monkey scans was greater than that in humans for organs with high PBR densities. For this reason, the human effective dose was overestimated by 60% with monkey biodistribution data. The monkey with receptor blockade had an overall distribution qualitatively similar to that of the unusual human subject (subject 7), with decreased exposure to lungs, kidney, and spleen. Conclusion: The effective dose of 11C-PBR28 was modest and was similar to that of several other 11C-radioligands. Lack of receptor binding in the unusual human subject and in the monkey with receptor blockade decreased exposure to organs with high PBR densities and enhanced uptake in excretory and metabolic pathways.
Key Words: translocator protein (18 kDa) • source organ • 11C-PBR28 • PET
COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  R. M. Bartlett, R. J. Nickles, T. E. Barnhart, B. T. Christian, J. E. Holden, and O. T. DeJesus Fetal Dose Estimates for 18F-Fluoro-L-Thymidine Using a Pregnant Monkey Model J. Nucl. Med., February 1, 2010; 51(2): 288 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kumar, O. Muzik, D. Chugani, P. Chakraborty, and H. T. Chugani PET-Derived Biodistribution and Dosimetry of the Benzodiazepine Receptor-Binding Radioligand 11C-(R)-PK11195 in Children and Adults J. Nucl. Med., January 1, 2010; 51(1): 139 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Seneca, S. S. Zoghbi, J.-S. Liow, W. Kreisl, P. Herscovitch, K. Jenko, R. L. Gladding, A. Taku, V. W. Pike, and R. B. Innis Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein J. Nucl. Med., May 1, 2009; 50(5): 807 - 813. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | RSS | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
